SureTrader SureTrader
Home > Boards > US Listed > Medical - Drugs >

Generex Biotechnology (GNBT)

GNBT RSS Feed
Add GNBT Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board:
Last Post: 9/16/2016 1:09:49 PM - Followers: 215 - Board type: Free - Posts Today: 0


 

Welcome to Generex

Generex Biotechnology Corporation is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device. The Company's buccal insulin spray product, Generex Oral-lyn™ is in Phase III clinical trials at several sites around the world.

Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases. Antigen Express has pioneered the use of specific CD4+ T helper stimulation in immunotherapy. One of its platform technologies relies on inhibition of expression of the Ii protein. Antigen Express scientists, and others, have shown clearly that suppression of expression of the Ii protein in cancer cells allows for potent stimulation of T helper cells and prevents the further growth of cancer cells. For more information about Antigen Express visit www.antigenexpress.com.

Mission Statement

Our mission is to develop innovative drug delivery technologies and drugs that will improve the quality
of life for people who suffer from disease.

Management Team


Mark Fletcher
President & Chief Executive Officer

Mark Fletcher, Esq. Mr. Fletcher was appointed as President and Chief Executive Officer in March 2011 and has served and continues to serve as Secretary since September 2010 and as General Counsel since April 2003.  Mr. Fletcher was appointed as Interim President/Chief Executive Officer and Secretary in September 2010.  In April 2003, he took the position of Executive Vice President and General Counsel with Generex.  From October 2001 to March 2003, Mr. Fletcher was engaged in the private practice of law as a partner at Goodman and Carr LLP, a leading Toronto law firm. From March 1993 to September 2001, Mr. Fletcher was a partner at Brans, Lehun, Baldwin LLP, a law firm in Toronto. Mr. Fletcher received his LL.B. from the University of Western Ontario in 1989 and was admitted to the Ontario Bar in 1991.  The Board believes that Mr. Fletcher's wide-ranging legal knowledge and extensive experience as a practicing lawyer, combined with his managerial skills and business acumen and judgment, provide our Board with valuable legal and operational expertise and leadership skills.
 
Dr. David Brusegard Ph.D
Chief Operating Officer (COO)

Dr. Brusegard has a breadth of experience in several fields of endeavour including, medical record design, health informatics, health insurance, digital mapping, database design, global positioning systems applications, business management and strategic planning. He was a senior economist at Statistics Canada for a decade, an adjunct professor at the University of Toronto and taught information ethics and information law at Ryerson University. He has consulted internationally on information management for the World Bank as well as major consumer packaged goods companies, hospitals, municipalities, and all levels of government. Recent positions of note include; Vice President, Analytics for ICOM Communication and Information, President of Geographic Decision Support Systems, CEO, Tristar Software, and CEO of the Pentius Group (a 5 company health insurance and managed care portfolio).

Dr. Brusegard's graduate work was carried out at The University of North Carolina at Chapel Hill, and the University of Calgary from which he holds a Ph.D. Phil.

Stephen Fellows
Acting Chief Financial Officer (CFO)

Mr. Fellows has over 20 years of experience in financial management and accounting reporting for both public and private companies, including debt and equity financings. As Acting Chief Financial Officer, he is instrumental in helping to direct and oversee Company financial and accounting procedures while providing strategic planning for creating future revenue streams including joint ventures and licensing arrangements for the Company's current portfolio of products as well as its product development pipeline.

Prior to joining Generex, Mr. Fellows spent almost four years at Sona Mobile Holdings Corporation, a publicly held software company which developed software applications for mobile devices, where he served as Chief Financial Officer. Mr. Fellows joined Sona Mobile from 3Com Corporation, where he was the Director of Finance of the corporate accounting group in Marlborough, MA. Prior to that, Mr. Fellows spent five years as the Director of Finance & Operations of 3Com's Canadian subsidiary. Mr. Fellows joined 3Com from Pennzoil Corporation where he spent time in the international mergers and acquisitions group in Houston, Texas, as well as four years as Controller for Pennzoil Canada.

Mr. Fellows holds a Bachelor of Business Administration degree from Wilfrid Laurier University in Waterloo, Ontario, Canada and earned his Chartered Accountants designation while articling with Arthur Andersen & Company in Toronto.

Dr. Eric von Hofe, Ph.D.
Vice-President of Generex and President of Antigen Express

Dr. Eric von Hofe, has been President of Antigen Express since April 2005. He joined Antigen in November 2003 as Vice President of Technology Development of Antigen. He has extensive experience with technology development projects, including his previous positions at Millennium Pharmaceuticals first as Program Director for Target Validation and later as Director of Programs & Operations, Discovery Research. Prior to that, Dr. von Hofe was Director, New Targets at Hybridon, Inc., where he coordinated in-house and collaborative research that critically validated gene targets for novel antisense medicines. Dr. von Hofe also held the position of Assistant Professor of Pharmacology at the University of Massachusetts Medical School, where he received a National Cancer Institute Career Development Award for defining mechanisms by which alkylating carcinogens create cancers. He received his Ph.D. from the University of Southern California in Experimental Pathology and was a postdoctoral fellow at both the University of Zurich and Harvard School of Public Health. His work has been published in forty-seven articles in peer-reviewed journals, and he has been an inventor on four patents.

Dr. Gerald Bernstein, M.D.
VP Medical Affairs

Gerald Bernstein,M.D., F.A.C.P. Graduated from Dartmouth College and Tufts University School of medicine. He is board certified in internal medicine (1966) and endocrinology and metabolism (1973). He entered practice in 1966 after completing a research fellowship. Dr. bernstein is an associate clinical professor at Albert Einstein College of Medicine in New York. He is an attending physician at Beth Israel Medical Center, Lenox Hill Hospital (1974) and Montefiore Medical Center (1966). He served on the National Board of Directors of the American Diabetes Association, its research foundation and many national committees. He was on the editorial board of the publication "Clinical Diabetes". He has been president of the New York Downstate affiliate of the American Diabetes Association. He is the author of many papers, clinical and scientific and the book "If it runs in your family: Diabetes Mellitus, Reducing your Risk". Dr. Bernstein is a past president of the American Diabetes Association and was Director of the Beth Israel Health Care Systems Diabetes Management Program. He is currently Director of the Diabetes Management Program of The Friedman Diabetes Institute at Beth Israel Hospital in New York. He has served as Vice President for Medical Affairs at Generex Biotechnology Corp. Since 2001.

Dr. Jaime Davidson, M.D.
Medical Director

Dr. Jaime Davidson, MD., F.A.C.P. was appointed a consultant Medical Director for Generex in July, 2006. Dr. Davidson is the President of Endocrine and Diabetes Associates of Texas, based at the Medical City Dallas Hospital complex, and a Clinical Associate Professor of Internal Medicine at University of Texas Southwestern Medical Center in Dallas, Texas. Dr. Davidson chaired the Diabetes Consensus Guidelines for the American College of Endocrinology and serves as Director of the Annual Intensive Diabetes, Endocrinology and Metabolic Diseases Course for the University of Southern California Keck School of Medicine. He serves as a council member for the Texas Department of Health Services, appointed by Texas Governor Rick Perry. In 2006 Dr. Davidson was distinguished by the American Association of Clinical Endocrinologists with an award for his contributions to the improvement of endocrine health for under-served populations, and by the American Diabetes Association with the Harold Rifkin MD award for his international contributions in the diabetes field. In the past, he has held positions with the National Diabetes Advisory Board, the National Institutes of Health, the Centers for Disease Control, the Institute of Medicine, and the boards of directors of the American Diabetes Association, the American Association of Clinical Endocrinologists, and the American College of Endocrinology. He served in higher education for a six year term as a Regent of Midwestern State University in Texas appointed by then Governor George W. Bush. He has also served in the President's Council for Fitness and Sports, chaired the Texas Diabetes Council of the Texas Department of Health for several years where he instituted the Texas Diabetes Algorithm, and under his guidance the Texas Diabetes Institute was established with the University of Texas Health Science Center in San Antonio, Texas. Dr. Davidson's experience in clinical pharmacology began with a Clinical Pharmacology Fellowship at Lilly Laboratories for Clinical Research and it continued with multiple clinical trials. In addition, he was an advisor to the Food and Drug Administration (FDA) on the Endocrinology and Metabolism Advisory Board. Dr. Davidson's Internal Medicine training was completed at Scott and White Hospital (now known as Texas A&M University) and his Endocrinology training at University Of Indiana.
 

Pipeline

Generex is currently conducting pre-clinical and human clinical trials using its proprietary technology platforms in the areas of diabetes, pain management and cancers.

               





Generex
     

Technology


Generex has two platform technologies in the area of drug delivery and immunomedicines.

Drug Delivery - RapidMist™:

Comprised of a proprietary device & pharmaceutical agents in an aerosolized liquid formulation.

Delivered through the buccal mucosa (inner cheek of mouth) and NOT THE LUNGS.

Applicable to most proteins and peptides.

 
 
Immunomedicines:

Antigen Express technology focuses on modulating immune responses mediated by T helper (Th) cells, a class of lymphocytes that plays a multifaceted role in the immune system, both enhancing and suppressing immune responses. The cells are essential both for obtaining a robust and long lasting response against infectious agents or cancer cells and for down regulating immune responses when the immune system becomes inappropriately stimulated, e.g. in autoimmune disease and allergy.








 

Antigen Express


Antigen Express is a platform technology and product-based company developing proprietary vaccine formulations for active immunotherapy as well as disease prevention.

In contrast to traditional therapies, the goal of active immunotherapy is to amplify the patients' ability to fight specific disease rather than targeting the diseased tissue or pathogenic agent directly. The novel technologies being developed at Antigen Express allows for robust and antigen-specific stimulation of CD4+ T cells, a cell type critical in the recognition of pathogens and modulation of the immune response.

Antigen Express is developing these technologies for application to the treatment of cancer, infectious diseases, and other serious diseases. Our most advanced vaccine utilizes a self-potentiating peptide as an off-the-shelf product for active immunotherapy of breast and prostate cancer

To find out more on Antigen Express please go to www.antigenexpress.com.

{C}


Eric von Hofe, PhD
President

Dr. von Hofe joined Antigen Express in November of 2003. Prior to this time he held two positions at Millennium Pharmaceuticals; first as Program Director for Target Validation, where he presided over technology development efforts for Aventis and Cereon, and second as Director of Programs and Operations, Discovery Research. He received his Ph.D. from the University of Southern California and was a postdoctoral fellow at the University Hospital of Zurich and Harvard. From 1989 to 1992 he was Assistant Professor of Pharmacology at the University of Massachusetts Medical School.

Robert E. Humphreys, MD, PhD
Founder (retired)

Dr. Humphreys was the Chief Scientific Officer of Antigen Express from it's inception, and at the time of his retirement held the position of Executive Vice President. Prior to joining Antigen Express, he was Professor of Pharmacology and Medicine, and interim Chair of Pharmacology at the University of Massachusetts Medical School. He received his BS, PhD and MD at Yale, and served in the US Navy at the US Naval Hospital and Naval Medical Research Institute in Bethesda. He was a postdoctoral fellow of Dr. Jack Strominger at Harvard. He has published over 140 peer-reviewed papers and has served 10 years on NIH study sections.

Catherine Blackwell
Business Operations Manager

Catherine Blackwell became a member of Antigen Express in January of 2004. She is responsible for managing the business operations of Antigen Express along with grants management and human resources. Preceding her position at Antigen Express, she was the project coordinator and accounting manager for Cyagra Incorporated, a biotechnology company specializing in agricultural cloning. She received her Bachelors degree in Veterinary Science in 1987 from the University of Massachusetts and a Masters degree in Education in 1991 from Anna Maria College.


 

Partners

Generex is dedicated to the research, development and commercialization of drugs delivery via the buccal mucosa. Generex seeks to out-license its RapidMist™ product programs and identify in-licensing opportunities and acquisitions in the areas of diabetes, drug delivery, cancer, H5 avian influenza, HIV, generic and branded prescription drugs, 505(b)2 product candidates, and late stage development opportunities.

Here are some of the companies we have partnered with; Please click on logos the get the details.

Medipharma S.A.


From its beginnings in 1982 Medipharma S.A. (www.medipharma.com.ar) is dedicated to the development and pharmaceutical product elaboration for human consumption, taking quality as the basic premise. Thus its Productive facilities, Laboratory of Quality and Microbiological Control have evolved continuously according to the more outpost norms from quality assurance (GMP - Good Practices of Manufacture), always with constant efforts in Investigation and Development. Several of our products count on studies of bioavailability approved by the Argentine sanitary authorities. This action of almost three decades, has allowed us to enter like suppliers of all the great welfare centers of the country and more recently to strengthen in the ethical market. The laboratory of Quality Control counts on equipment that allows us to compliment with the international norms as far as analytical and microbiological controls. Our productive areas count on equipment and personnel that have distinguished us in the medicine production of high risk (low product concentration with dangerous pharmacologic limits, for example digoxin) Complimenting GMP 2002, our company has all its productive and control equipment qualificated as well as all its productive and cleaning processes validated (reviewed and approved by our national authorities in 2005). We have also signed agreements of Investigation and Development with the C.O.N.I.C.E.T. and the National University of La Plata, for the obtaining of active principles of last generation.  One of the research groups working on a calcium supplement directed to stimulate the passive absorption, independent of age and hormonal status of the patient, stimulating the gastrointestinal absorption of calcium through the formation of a micelle in situ transportable via passively into the bloodstream, independent of vitamin D and / or estrogen intake. This research is oriented towards the prevention and / or treatment of osteoporosis.  The other research group studies a new derivative of valproic acid molecule which by its molecular structure allows cross the blood-brain barrier. This new molecule will allow the health professional to manage a dosage regimen involving the administration to patients of up to 100 times lower dose of valproic acid, than those used with existing molecules, reducing the adverse effects associated with toxicity of the same.

Sanofi-aventis
Sanofi-aventis (www.sanofi-aventis.com), a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

 



Merck Serono

Merck Mexico (www.merckserono.com) was founded in 1930 as one of the first pharmaceutical producers in Mexico. Today, with close to 1,035 employees, Merck, S.A. de C.V. manufactures and sells a great variety of products for the treatment pain, diabetes, thyroid problems, colds, growth hormone, multiple sclerosis and cancer, among other diseases. In its chemical area, Merck has specialty pigments and active ingredients for the cosmetics industry.


Dong Sung Pharmaceuticals

Dong Sung Pharmaceuticals (www.dongsung-pharm.co.kr/eng), founded in 1957, is one of Korea's leading pharmaceutical companies with more than 500 employees and the largest production facilities in the country.



Catalent

Catalent (www.catalent.com) is a leading provider of advanced dose form and packaging technologies, and development, manufacturing, packaging and printing services for pharmaceutical, biotechnology and consumer healthcare companies in nearly 100 countries. Catalent applies its local market expertise and technical creativity to advance treatments, change markets and enhance patient outcomes. Catalent employs approximately 9,000 at 29 facilities worldwide and in fiscal 2010 generated more than $1.7 billion of annual revenue.





Adcock Ingram

Adcock Ingram (www.adcock.co.za), part of the Tiger Brands Group, is a leading South African pharmaceutical company with an 11.4% share of the private healthcare market. Adcock Ingram has an extensive range of prescription, generic, and over-the-counter products and also provides life saving hospital equipment and diagnostic products and services.



Shreya Life Sciences Pvt

Shreya Life Sciences Pvt. Ltd. (www.shreya.co.in), a leading Indian-based pharmaceutical company. Shreya is the fourth largest distributor of insulin in the Indian insulin product market with a compound annual growth rate of 38% (per C MARC market research). Shreya has interests in both pharmaceutical and biopharmaceutical products in key therapeutic segments including cardiology, neuropathy, and diabetes. The company has business operations in India, Russia, the Commonwealth of Independent States, and African countries. The parties are making arrangements for the expansion of extant production facilities to meet the anticipated demand for the product in India and other jurisdictions where governmental approvals are pending.




Investor Relations

For more information please contact:
Todd Falls
Tel: 1-800-391-6755
Fax: (647) 547-7104
Email: tfalls@generex.com


Exchange

OTC Bulletin Board

Listed Security

GNBT Common Stock

Transfer Agent

StockTrans, Inc.
44 West Lancaster Avenue
Ardmore, PA 19003
Phone 610-649-7300
Fax 610-649-7302

Corporate Counsel

Eckert Seamans Cherin & Mellott, LLC
1515 Market Street, 9th Floor
Philadelphia, PA 19102
Phone 215-851-8447
Fax 215-851-8383

RULES of THE ROAD
All messages, including I-box content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
 
Also, keep in mind that moderators may or may not have a position in said stock. 
 
Please keep your posts on topic because your message(s) may be removed when:
► Posting content that's off-topic to the subject of this board;
► Posting statements that don't add value to the discussion; or
► When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp
http://ihwiki.advfn.com/index.php?title=Handbook#Deletion_of_Posts


 


  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
GNBT
Current Price
Volume:
Bid Ask Day's Range
SureTrader
PostSubject
#5932   A 4.57% rise so far today - any DrDouglas 09/16/16 01:09:49 PM
#5931   Lol, ole Natalie speaks like a true puta. Monroe1 09/13/16 01:16:20 PM
#5930   "Joe got married." The irony :o) grobtekrebssvindl 09/13/16 09:54:11 AM
#5929   So old Joe got married. I wonder if Monroe1 09/09/16 12:16:05 PM
#5928   Scam?Fraud! grobtekrebssvindl 08/05/16 06:10:01 PM
#5927   This has been a scam for years. ice coffee 08/04/16 08:56:32 PM
#5926   Game is over! grobtekrebssvindl 08/03/16 09:26:48 PM
#5925   Not sure. No real news coming out of sirglenn 08/03/16 02:11:20 PM
#5924   So what is the market for the Oral Monroe1 08/03/16 12:10:37 PM
#5923   GNBT is undervalued & has potential for future Poundthetable 07/25/16 01:14:35 PM
#5922   Beware!P&D Spam, SCAM!! I keep getting spammed in Simoleons 07/25/16 12:42:48 PM
#5921   THE MILATARY WILL LOVE THIS seriousonly 07/24/16 12:07:12 PM
#5920   thanky ou/ Generex Biotechnolog (GNBT) mick 07/16/16 01:24:49 PM
#5919   What is there story? Quacker 07/15/16 08:56:06 PM
#5918   Nice find GoodWill 07/15/16 01:30:18 PM
#5917   http://www.barchart.com/quotes/stocks/GNBT mick 07/10/16 11:26:18 AM
#5916   brewing IN The Mouth Of Madness 07/08/16 04:15:13 PM
#5915   really? how mcnugget 07/08/16 11:33:49 AM
#5914   Gnbt is a horrible company. Its only up ice coffee 07/05/16 03:04:44 PM
#5913   Is there anyone else excited by the fact sirglenn 07/05/16 01:08:01 PM
#5912   reading, interesting/ 'Generex Biotechnology (GNBT)' mick 06/27/16 01:11:21 PM
#5911   agreed IN The Mouth Of Madness 06/22/16 10:24:39 PM
#5910   One big sale of 2mm+@.007. Would be Gassillios 06/21/16 01:07:13 AM
#5909   There has been some decent volume here for sirglenn 06/20/16 04:02:52 PM
#5907   I had also noticed the Hema article, but houvp 06/18/16 03:51:22 PM
#5906   Im surprised the sec hasnt shut this scam ice coffee 06/17/16 11:29:24 PM
#5905   Hey, I know the PR was old, but sirglenn 06/17/16 04:53:48 PM
#5904   I'm new to this stock today.. what's through Araskal 06/17/16 03:31:44 PM
#5903   100 share whack @ 0086. Bidder will have mean weimeraner 06/17/16 11:29:23 AM
#5902   Lil under 300k left @ 009, breaks soon mean weimeraner 06/17/16 11:05:53 AM
#5901   $GNBT .009 FALLING mean weimeraner 06/17/16 10:51:37 AM
#5900   400K BUY @ 0089 mean weimeraner 06/16/16 04:44:45 PM
#5899   700k bids at .008.... mean weimeraner 06/16/16 01:12:56 PM
#5898   break 009 on volume, I'm a buyer IN The Mouth Of Madness 06/16/16 12:40:14 AM
#5897   I love PRS almost a ur old keep starkd748 06/15/16 06:32:32 PM
#5896   Dude that PR is almost a yr old starkd748 06/15/16 06:31:00 PM
#5895   $GNBT 6.8m bidder moved up from 0056 ~ mean weimeraner 06/15/16 04:56:12 PM
#5894   Thanks. Well, someone knows something here. It keeps sirglenn 06/15/16 03:18:56 PM
#5893   Nice find mean weimeraner 06/15/16 01:49:54 PM
#5892   Well I found it. Here is a link sirglenn 06/15/16 11:34:18 AM
#5891   Is there a verifiable reason why this is sirglenn 06/14/16 12:15:47 PM
#5890   Not sure where you heard that but this mean weimeraner 06/10/16 07:51:12 AM
#5889   Is the Zika virus vaccine information verifiable? That sirglenn 06/09/16 05:35:03 PM
#5888   Ehhh Dkempel 06/09/16 03:22:00 PM
#5887   ANTIGEN EXPRESS HAS THE ZIKA VIRUS VACCINE. Spooch07 06/09/16 12:38:11 AM
#5885   Considering there is basically no short shares from bbarbbee 06/08/16 09:34:26 PM
#5884   Im out of this finally, GL all GhostInTheMatrix 06/08/16 04:57:46 PM
#5883   yes somethings going on, lot of buys out mcnugget 06/08/16 12:01:43 PM
#5882   nice am volume, holding gains well. next push IN The Mouth Of Madness 06/08/16 10:11:14 AM
#5881   holding gains well, next push to 0097, once IN The Mouth Of Madness 06/08/16 10:09:01 AM
PostSubject